Hydroxychloroquine-induced acute generalized exanthematous pustulosis: a series of seven patients and review of the literature.
Journal
International journal of dermatology
ISSN: 1365-4632
Titre abrégé: Int J Dermatol
Pays: England
ID NLM: 0243704
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
07
12
2020
received:
25
08
2020
accepted:
29
12
2020
pubmed:
19
2
2021
medline:
22
6
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
Hydroxychloroquine (HCQ)-induced acute generalized exanthematous pustulosis (AGEP) is poorly described in the literature. The aim of our study was to characterize the clinical, laboratory, allergological, and genetic features of HCQ-induced AGEP. We conducted a retrospective study of patients with HCQ-induced AGEP diagnosed between 2011 and 2019. We performed molecular analysis to identify variations in the IL36RN gene. We also reviewed similar cases reported between 1991 and March 2020. Seven female patients were included. The mean age was 47 years old, and the average time from HCQ start to onset of symptoms was 40 days. All patients received topical steroids with a full resolution of the rash within an average of 39 days after HCQ withdrawal. Patch tests were performed for three patients with positive results in one case. Genetic analyses were performed for three patients, and no mutation in the IL36RN gene was identified. The latent period and the duration for resolution of HCQ-induced AGEP may be longer than with other drugs due to the metabolic characteristics of HCQ. Mutations in the IL36RN gene were not identified in our patients.
Sections du résumé
BACKGROUND
BACKGROUND
Hydroxychloroquine (HCQ)-induced acute generalized exanthematous pustulosis (AGEP) is poorly described in the literature. The aim of our study was to characterize the clinical, laboratory, allergological, and genetic features of HCQ-induced AGEP.
METHODS
METHODS
We conducted a retrospective study of patients with HCQ-induced AGEP diagnosed between 2011 and 2019. We performed molecular analysis to identify variations in the IL36RN gene. We also reviewed similar cases reported between 1991 and March 2020.
RESULTS
RESULTS
Seven female patients were included. The mean age was 47 years old, and the average time from HCQ start to onset of symptoms was 40 days. All patients received topical steroids with a full resolution of the rash within an average of 39 days after HCQ withdrawal. Patch tests were performed for three patients with positive results in one case. Genetic analyses were performed for three patients, and no mutation in the IL36RN gene was identified.
CONCLUSION
CONCLUSIONS
The latent period and the duration for resolution of HCQ-induced AGEP may be longer than with other drugs due to the metabolic characteristics of HCQ. Mutations in the IL36RN gene were not identified in our patients.
Substances chimiques
IL36RN protein, human
0
Interleukins
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
742-748Informations de copyright
© 2021 the International Society of Dermatology.
Références
Roujeau J-C. Acute generalized exanthematous pustulosis: analysis of 63 cases. Arch Dermatol 1991; 127: 1333.
Halevy S, Kardaun SH, Davidovici B, et al.; for the EuroSCAR and RegiSCAR Study Group. The spectrum of histopathological features in acute generalized exanthematous pustulosis: a study of 102 cases: Histopathological features in AGEP. Br J Dermatol 2010; 163: 1245-1252.
Alia E, Grant-Kels JM. Does Hydroxychloroquine Combat COVID-19? A Timeline of Evidence. J Am Acad Dermatol 2020; 83: e33-e34.
Sidoroff A, Halevy S, Bavinck JNB, et al. Acute generalized exanthematous pustulosis (AGEP) - A clinical reaction pattern. J Cutan Pathol 2001; 28: 113-119.
Kawasaki E, Erlich H. EDITORIALS: polymerase chain reaction and analysis of cancer cell markers. JNCI J Natl Cancer Inst 1990; 82: 806-807.
Barbaud A, Goncalo M, Bruynzeel D, et al. Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactions. Proposed by the Working party of the ESCD for the study of skin testing in investigating cutaneous adverse drug reactions. Contact Dermatitis 2001; 45: 321-328.
Bahloul E, Jallouli M, Garbaa S, et al. Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases. Lupus 2017; 26: 1304-1308.
Sharma AN, Mesinkovska NA, Paravar T. Characterizing the adverse dermatologic effects of hydroxychloroquine: a systematic review. J Am Acad Dermatol 2020; 83: 563-578.
Sidoroff A, Dunant A, Viboud C, et al. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). Br J Dermatol 2007; 157: 989-996.
Fernández-Ruiz M, López-Medrano F, García-Ruiz F, et al. Diltiazem-induced acute generalized exanthemic pustulosis: a case and review of the literature. Acta Dermosifiliogr 2009; 100: 725-727.
Ross CL, Shevchenko A, Mollanazar NK, et al. Acute generalized exanthematous pustulosis due to terbinafine. Dermatol Ther 2018; 31: e12617.
Di Maso V, Cozzi M, Gerini U, et al. Coupled plasma filtration adsorption for treatment of capillary leak syndrome superimposed to acute generalized exanthematous pustolosis: a case report. Blood Purif 2020; 49: 372-378.
Di Lernia V, Grenzi L, Guareschi E, et al. Rapid clearing of acute generalized exanthematous pustulosis after administration of ciclosporin. Clin Exp Dermatol 2009; 34: e757-e759.
Liccioli G, Marrani E, Giani T, et al. The first pediatric case of acute generalized exanthematous pustulosis caused by hydroxychloroquine. Pharmacology 2019; 104: 57-59.
Munster T, Gibbs JP, Shen D, et al. Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1460-1469.
Soria A, Barbaud A, Assier H, et al. Cutaneous adverse drug reactions with antimalarials and allergological skin tests. Dermatology 2015; 231: 353-359.
Pearson KC, Morrell DS, Runge SR, et al. Prolonged pustular eruption from hydroxychloroquine: an unusual case of acute generalized exanthematous pustulosis. Cutis 2016; 97: 212-216.
İslamoğlu ZGK, Karabağli P. A case of recalcitrant acute generalized exanthematous pustulosis with Sjogren’s syndrome: successfully treated with low-dose cyclosporine. Clin Case Rep 2019; 7: 1721-1724.
Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol 2015; 73: 843-848.
Bailey K, Mckee D, Wismer J, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: first case report in Canada and review of the literature. J Cutan Med Surg 2013; 17: 414-418.
Navarini AA, Valeyrie-Allanore L, Setta-Kaffetzi N, et al. Rare Variations in IL36RN in Severe Adverse Drug Reactions Manifesting as Acute Generalized Exanthematous Pustulosis. J Invest Dermatol 2013; 133: 1904-1907.
Navarini AA, Simpson MA, Borradori L, et al. Homozygous Missense Mutation in IL36RN in Generalized Pustular Dermatosis With Intraoral Involvement Compatible With Both AGEP and Generalized Pustular Psoriasis. JAMA Dermatol 2015; 151: 452.
Barbaud A, Collet E, Milpied B, et al. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions: drug patch tests for SCAR. Br J Dermatol 2013; 168: 555-562.
Salman A, Yucelten D, Akin Cakici O, et al. Acute generalized exanthematous pustulosis due to ceftriaxone: report of a pediatric case with recurrence after positive patch test. Pediatr Dermatol 2019. https://doi.org/10.1111/pde.13838
Phillips EJ, Bigliardi P, Bircher AJ, et al. Controversies in drug allergy: testing for delayed reactions. J Allergy Clin Immunol 2019; 143: 66-73.
Barbaud A. Skin Testing and Patch Testing in Non-IgE-Mediated Drug Allergy. Curr Allergy Asthma Rep 2014; 14: 442.
Kardaun SH, Kuiper H, Fidler V, et al. The histopathological spectrum of acute generalized exanthematous pustulosis (AGEP) and its differentiation from generalized pustular psoriasis. J Cutan Pathol 2010; 37: 1220-1229.
Assier-Bonnet H, Saada V, Bernier M, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine. Dermatology 1996; 193: 70-71.
Evans CC, Bergstresser PR. Acute generalized exanthematous pustulosis precipitated by hydroxychloroquine. J Am Acad Dermatol 2004; 50: 650-651.
Martins A, Lopes LC, Paiva Lopes MJ, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine. Eur J Dermatol 2006; 16: 317-318.
Paradisi A, Bugatti L, Sisto T, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: three cases and a review of the literature. Clin Ther 2008; 30: 930-940.
Avram MM, Hoang M. Case 20-2009: A 79-Year-Old Woman with a Blistering Cutaneous Eruption. N Engl J Med 2009; 360: 2771-2777.
Park J-J, Yun SJ, Lee J-B, et al. A Case of Hydroxychloroquine Induced Acute Generalized Exanthematous Pustulosis Confirmed by Accidental Oral Provocation. Ann Dermatol 2010; 22: 102.
Charfi O, Kastalli S, Sahnoun R, et al. Hydroxychloroquine-induced acute generalized exanthematous pustulosis with positive patch-testing. Indian J Pharmacol 2015; 47: 693.
Zhang Z, Liu X. Acute generalized exanthematous pustulosis. N Engl J Med 2015; 372: 161.
Yalçın B, Çakmak S, Yıldırım B. Successful treatment of hydroxychloroquine-induced recalcitrant acute generalized exanthematous pustulosis with cyclosporine: case report and literature review. Ann Dermatol 2015; 27: 431.
Castner NB, Harris JC, Motaparthi K. Cyclosporine for corticosteroid-refractory acute generalized exanthematous pustulosis due to hydroxychloroquine. Dermatol Ther 2018; 31: e12660.
Duman H, Topal IO, Kocaturk E, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine: a case with atypical clinical presentation. An Bras Dermatol 2017; 92: 404-406.
Mohaghegh F, Jelvan M, Rajabi P. A case of prolonged generalized exanthematous pustulosis caused by hydroxychloroquine-Literature review. Clin Case Rep 2018; 6: 2391-2395.
Matsuda-Hirose H, Sho Y, Yamate T, et al. Acute generalized exanthematous pustulosis induced by hydroxychloroquine successfully treated with etretinate. J Dermatol 2020; 47.